RELPAX SUMMARY
RELPAX® (eletriptan hydrobromide) Tablets
RELPAX® (eletriptan) Tablets contain eletriptan hydrobromide, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults.
RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Relpax (Eletriptan)
Rhinitis exacerbates migraine
Source: Allergy News From Medical News Today [2013.11.27]
People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati (UC), Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.
Nasal Allergies, Hay Fever Tied to More Migraines in Study
Source: MedicineNet Allergy Specialty [2013.11.26]
Title: Nasal Allergies, Hay Fever Tied to More Migraines in Study
Category: Health News
Created: 11/26/2013 9:35:00 AM
Last Editorial Review: 11/26/2013 12:00:00 AM
What Not to Do for Migraines
Source: MedicineNet Headache Specialty [2013.11.21]
Title: What Not to Do for Migraines
Category: Health News
Created: 11/21/2013 9:35:00 AM
Last Editorial Review: 11/21/2013 12:00:00 AM
Migraine sufferers more likely to have depression
Source: Headache / Migraine News From Medical News Today [2013.10.18]
A large new study from Canada finds that people who suffer from migraines are also more likely to have depression and think about suicide than counterparts who do not have them.
'Dechronifying' chronic migraine: Detox then treat
Source: Headache / Migraine News From Medical News Today [2013.10.14]
"Worldwide, headache affects approximately 50% of adults each year. Approximately 11% of cases meet the criteria for migraine," Prof Paolo Martelletti (Rome, Italy) said today, speaking at the Congress of the European Pain Federation EFIC in Florence. "In Europe and America, we estimate the prevalence of migraine to be 6 to 8% in men and 15 to 18% in women.
Published Studies Related to Relpax (Eletriptan)
Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. [2007.02]
OBJECTIVE: To compare the efficacy and tolerability of eletriptan 20 mg, 40 mg, and 80 mg in triptan-naive patients (who have not previously used triptans) versus triptan-experienced patients (who have previously used triptans)... CONCLUSIONS: These data suggest that eletriptan has comparable efficacy versus placebo among both triptan-naive and triptan-experienced patients.
Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. [2006.03]
Preference is a composite, patient-oriented endpoint incorporating efficacy, tolerability, formulation, and convenience of medications. The objective of this study was to compare patient preference for rizatriptan 10-mg wafer vs... The single most important reason for preference was speed of relief, consistent with results from previous preference studies.
Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. [2005.09]
This double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of early treatment of a single migraine attack, when headache pain was mild, with two doses (20 mg and 40 mg) of eletriptan. Patients (N = 613; female 79%; mean age 39 years) meeting International Headache Society criteria for migraine were encouraged, but not required, to utilize early treatment, thus providing an opportunity to assess the relative contribution to efficacy of pain severity and timing of dose...
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. [2005.02]
This current randomized, open-label, crossover study evaluated preference for oral eletriptan 80 mg compared with subcutaneous sumatriptan 6 mg (suma-sc) amongst patients (n = 311) meeting IHS criteria for migraine who had recently used suma-sc, and found it well tolerated... The results of this study suggest that eletriptan is a strong alternative option for patients who have been prescribed suma-sc.
No effect of eletriptan administration during the aura phase of migraine. [2004.10]
Migraine aura is a warning sign readily recognized by patients... This study confirms the findings of two studies showing that triptans are ineffective but safe when given during the migraine aura phrase.
Clinical Trials Related to Relpax (Eletriptan)
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine [Completed]
A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine [Completed]
To evaluate the efficacy of early intervention (dosing within 2 hours of onset of the
migraine attack) with eletriptan 40mg on mild versus moderate to severe pain intensity of
migraine.
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan [Recruiting]
Women are followed prospectively for 3 months, recording headaches, other symptoms, and
menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan
for 3 months.
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy [Completed]
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were
not satisfied with rizatriptan therapy
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-Inflammatory Drugs [Completed]
To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who
had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)
Reports of Suspected Relpax (Eletriptan) Side Effects
Drug Ineffective (49),
Headache (47),
Migraine (47),
Feeling Abnormal (17),
Depression (15),
Chest Discomfort (13),
Nausea (11),
Fatigue (10),
Vomiting (10),
Pain in Extremity (9), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 6 ratings/reviews, Relpax has an overall score of 8. The effectiveness score is 8 and the side effect score is 8.33. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Relpax review by 47 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | migraine relief |
| Dosage & duration: | | 25mg taken 4x/month for the period of 3 years |
| Other conditions: | | n/a |
| Other drugs taken: | | n/a | | |
Reported Results |
| Benefits: | | migraine pain relieved in 1 - 2 hours and lasted for 24 hours with 1 tablet |
| Side effects: | | none |
| Comments: | | 1 tablet at first signs of headache |
|
| | Relpax review by 40 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Considerably Effective |
| Side effects: | | Mild Side Effects | | |
Treatment Info |
| Condition / reason: | | Migraines |
| Dosage & duration: | | can't remember (dosage frequency: 1 every 24 hrs as needed for migraine) for the period of once a month |
| Other conditions: | | n/a |
| Other drugs taken: | | Pristiq | | |
Reported Results |
| Benefits: | | It would ease the throbbing feeling associated with a migraine. |
| Side effects: | | Low blood pressure. |
| Comments: | | You could feel a marked difference in your blood pressure, that was the only negative side effect. Other than that, it helped calm the pulsating sensation you would get with an intense migraine. Helping you to relax and feel better. |
|
| | Relpax review by 39 year old female patient | | | Rating |
| Overall rating: | | |
| Effectiveness: | | Marginally Effective |
| Side effects: | | Moderate Side Effects | | |
Treatment Info |
| Condition / reason: | | migraine headaches |
| Dosage & duration: | | .5 (dosage frequency: 2 times per day) for the period of 3 days |
| Other conditions: | | none |
| Other drugs taken: | | birth control | | |
Reported Results |
| Benefits: | | The medication took almost thirty minutes to kick in. Once the medication started to take affect, I began to develop a tingling sensation in my left hand and later my right hand. I also noticed my hands were very shaky after the medication was in my system for at least an hour. |
| Side effects: | | The medication took almost thirty minutes to kick in. Once the medication started to take affect, I began to develop a tingling sensation in my left hand and later my right hand. I also noticed my hands were very shaky after the medication was in my system for at least an hour. |
| Comments: | | Once a migraine is formulating, one pill is to be taken. The medication took almost thirty minutes to kick in. Once the medication started to take affect, I began to develop a tingling sensation in my left hand and later my right hand. I also noticed my hands were very shaky after the medication was in my system for at least an hour. |
|
|
|
Page last updated: 2013-11-27
|
